Comparison of Expedited Reporting System for Investigational Drugs in the U .S., EU and South Korea
Journal of Pharmacoepidemiology and Risk Management · 2022
DOI: 10.56142/2022.14.1.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacoepidemiology and Risk Management, 2022. Verfasst von Ji Woo Cha und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Ji Woo Cha, BS, Ha Eun Rhee, BS, Sang-Jun Park, MS, Sanghee Kim, PhD, Hye Kyung Cho, Pharm.D, Jeong Eun Lee, MS, Bomi Lee, MS, Da-Young Shim, Pharm.D, MS and Ju-Young Shin, PhD. Journal of Pharmacoepidemiology and Risk Management 2022;14:11-8. https://doi.org/10.56142/2022.14.1.11
Zitieren
APA
Cha, J. W., Rhee, H. E., Park, S., Kim, S., Cho, H. K., Lee, J. E., Lee, B., Shim, D., & Shin, J. (2022). Comparison of Expedited Reporting System for Investigational Drugs in the U .S., EU and South Korea. Journal of Pharmacoepidemiology and Risk Management. https://doi.org/10.56142/2022.14.1.11
Vancouver
Cha JW, Rhee HE, Park S, Kim S, Cho HK, Lee JE, et al. Comparison of Expedited Reporting System for Investigational Drugs in the U .S., EU and South Korea. Journal of Pharmacoepidemiology and Risk Management. 2022. doi:10.56142/2022.14.1.11
BibTeX
@article{Cha2022,
author = {Cha, Ji Woo and Rhee, Ha Eun and Park, Sang-Jun and Kim, Sanghee and Cho, Hye Kyung and Lee, Jeong Eun and Lee, Bomi and Shim, Da-Young and Shin, Ju-Young},
title = {Comparison of Expedited Reporting System for Investigational Drugs in the U .S., EU and South Korea},
journal = {Journal of Pharmacoepidemiology and Risk Management},
year = {2022},
doi = {10.56142/2022.14.1.11}
}
EUVIMED